Rami hannoush. D General Information. Rami hannoush

 
D General InformationRami hannoush  Healthcare VC at Versant | Life sciences company creation | Former R&D leader, Genentech | Former CEO, EpiBiologics 6mo Edited Report this post Great chat with

Rami Hannoush, Ph. D. Developing tool ligands that target individual LRP6 domains could help elucidate the mechanism of. We cover Rami's new role at. Reprints and Permissions. There is no recent news or activity for this profile. com; PMID: 21964784 DOI: 10. Healthcare VC at Versant | Life sciences company creation | Former R&D leader, Genentech | Former CEO, EpiBiologics ٦ شهر الإبلاغ عن هذا المنشور. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 1 mes Denunciar esta publicación Denunciar Denunciar. Xinxin Gao 1 , Rami N Hannoush 1 Affiliation 1 Department of Early Discovery Biochemistry, Genentech, Inc. Hannoush. This is a mechanism that's been conserved throughout the animal kingdom,” explains Rami Hannoush, interim CEO and co-founder of EpiBiologics. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 6mo Edited Report this post It’s been a terrific two days at #jpm2023, meeting new talent and connecting with friends in pharma and the VC world. Over the weekend, I received the Outstanding Recent Alumnus Award alongside some incredibly accomplished individuals. The Frizzled (FZD) 7 receptor (FZD7) is enriched in LGR5 + intestinal stem cells and plays a critical role in their self-renewal. Its proprietary EpiTAC platform is a. Back. Rami Hannoush, Ph. A. Founded in 2022 and led by CEO Dr. Rami Hannoush, EpiBiologics is building a protein degradation platform that targets membrane and extracellular proteins. The company has headquarters in San Mateo, CA. 4 the Department of Early Discovery Biochemistry, Genentech, South San Francisco, California 94080, and hannoush. Coming out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. D. com. , South San Francisco, CA, USA. 2015. Department of Early Discovery Biochemistry, Genentech, South San Francisco, CA, United States. I had the pleasure to join Rob Faulkner and Soo Romanoff on a. Healthcare VC | Life sciences company creation 2yThe 2020 Chemistry and Biology of Peptides Gordon Research Conference will showcase the most recent, cutting edge research in advancing peptides as tools, materials, and therapeutics. rami@gene. Copy Link. D. Rami Hannoush: Franklin Berger — Eli Lilly — DCVC Bio . ’s Post Rami Hannoush, Ph. Expand search. Courtesy of EpiBiologics. Rami Hannoush 7mo Report this post 2021 Innovative Medicines Fifty new drugs were FDA approved that help improve the health of patients with unmet medical needs and protect. Rami Hannoush has been working as a Chief Executive Officer & Co-Founder & Member Board of Directors at EpiBiologics for 8 months. interim CEO and co-founder of EpiBiologics and venture partner at Versant Ventures. Expand search. “We would like to thank Rami Hannoush for his leadership as co-founder and interim CEO and look forward to an exciting next stage of growth for EpiBiologics under Ann’s leadership. Wnt ligands are critical for tissue homeostasis and form a complex with LRP6 and frizzled coreceptors to initiate Wnt/β-catenin signaling. Apply now and find other jobs on WIZBIIRami Hannoush, Ph. Joel P. D. THE AURON TEAM A CULTURE OF INNOVATION. Founded in 2022 and led by CEO Dr. The American Peptide Society, APS, a nonprofit scientific and educational organization founded in 1990, provides a forum for advancing and promoting knowledge of the chemistry and biology of peptides. “Dysregulation of normal cellular differentiation processes can alter normal cell biology leading to tumor formation and progression,” said Dr. Contents: Chemical Synthesis S2 . D. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 5mo EditedRami Hannoush, Ph. Corresponding author. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 7mo Report this post What are some of the factors that contribute to aging? And could we identify the specific mechanisms by which these factors impair tissue regeneration?Rami Hannoush, Ph. Supplementary Figure 2 S6 . Rami Hannoush, co-founder and interim CEO of EpiBiologics, discusses the company’s platform technology, how its protein degradation approach expands the potential targets for its therapies; and. BSMB Spring meeting 2022: "Interactions between Lipids/derivatives and the ECM: pre-clinical and clinical relevance" Registration for BSMB members is FREE, £10 and £30 respectively for student. Hannoush is an academic researcher from Genentech. “Jim and I have known each other for the past 15 years through Genentech collaborations. D. Epub 2021 Dec 10. Rami N. They found a peptide that converts the caspase to its inactive state—the zymogen—and traps it there, a bit like a wheel clamp. . Hannoush's 87 research works with 3,279 citations and 10,017 reads, including: Synthetic Multivalent Disulfide-Constrained Peptide Agonists Potentiate Wnt1/β-Catenin Signaling via LRP6. I am thankful for the LPs, founders, CEOs, team members who have remained steadfast partners over the years in using advanced technology to build a better… | 13 comments on LinkedInRami Hannoush, co-founder and interim CEO of EpiBiologics, discusses the company’s platform technology, how its protein degradation approach expands the potential targets for its therapies; and. When expanded it provides a list of search options that will switch the search inputs to match the. D. com. Schneider, National Cancer Institute – Center for Cancer Research. I am a Scientist in the Physiological Chemistry Department of Genentech's research organization. com. D. The WNT-FZD (W i n gless/In t 1-F ri z zle d) signaling system has a prevalent role in physiology during adulthood. ’s Post Rami Hannoush, Ph. In an interview with BioPharma Dive: Biotech and Pharma news, our co-founders Jim Wells and Rami Hannoush discussed the company's origin and EpiBiologics' differentiated protein degradation approach. Healthcare VC | Life sciences company creation 1y 2021 Innovative Medicines Fifty new drugs were FDA approved that help improve the health of patients with unmet medical needs. View the profiles of professionals named. Patrick Sexton, Monash University. When expanded it provides a list of search options that will switch the search inputs to match the. Gemma met Rami in 2011 when she was just starting out on the reality show The Only Way Is Essex. The company intends to use the funds to advance the lead program toward clinical development and drive additional programs into drug discovery. ’s Post Rami Hannoush, Ph. Currently teaching. The design of clickable fatty acid probes is based on the introduction of a small chemical tag (alkyne or azide) at the ω or methyl end of the fatty acid (Figure 2). Back. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 2mo Report this post Report Report. Alanna Schepartz, The University of California, Berkeley. The advent of click chemistry has propelled the field of protein palmitoylation forward by providing specific, sensitive, rapid, and easy-to-handle methods for studying protein pal. Rami N. 5 From the Section of Receptor Biology and Signaling, Department of Physiology and Pharmacology, Karolinska Institutet, S-171 77 Stockholm, Sweden, the Faculty of Science, Institute of Experimental. Palmitate can either be added to. D. … | 77 comments on LinkedInComing out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. Rami N Hannoush Adjunct Professor, Chemical and Systems Biology Operations Print Profile Email Profile Bio Bio Professional Contact. Rami Hannoush, Ph. Connect Alison Symington Strategic expertise in bringing innovation in the life sciences. Rami Hannoush, Dr. A fascinating approach to degrade membrane proteins/receptors. Jumi Shin, University of Toronto. ’s Post Rami Hannoush, Ph. Rami Hannoush, Ph. Coming out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. ’s Post Rami Hannoush, Ph. Stablix is pioneering an entirely new field of targeted deubiquitination therapeutics (TDT) to bring transformative medicines to patients with unmet medical need. The assay offers temporally resolved detection of Wnt-stimulated accumulation of beta-catenin, simultaneously detecting cell number, and it sheds light onto the kinetics of posttranslational. D. Back. Professor Nagy Habib is Head of Surgery at the Hammersmith Campus of Imperial College London and also a serial founder and entrepreneur of life sciences ventures. Back. Rami Hannoush, co-founder and interim CEO of EpiBiologics, discusses the company’s platform technology, how its protein degradation approach expands the potential targets for its therapies; and. Hannoush and Arenas-Ramirez, 2009; Martin and Cravatt, 2009) also showed efficient bioorthogonal labeling of fatty acyl-ated proteins. Coming out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. Rami Hannoush, Ph. Marianne Mertens, Ph. ’s Post Rami Hannoush, Ph. Rami Hannoush General Partner, Mubadala Capital | Life sciences company creation | Chief Scientific Officer 10mo EditedA multi-parametric method for quantitative analysis of cellular β-catenin protein levels in a rapid and high-throughput manner is described, which offers temporally resolved detection of Wnt-stimulated accumulation of β-Catenin, simultaneously detecting cell number, and it sheds light onto the kinetics of posttranslational stabilization ofβ-. Congrats Cameron! Like Reply 1 Reaction. Electronic address: hannoush. Introduction. D. The . Hannoush and Phil S. 1038/nchembio. Rami Hannoush is the co-founder, interim CEO and president of EpiBiologics. com. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 10mo EditedGreat chat with Ron Leuty from San Francisco Business Times to share our story on building EpiBiologics #companybuilding #degradation | 37 Kommentare auf LinkedInIn an interview with BioPharma Dive: Biotech and Pharma news, our co-founders Jim Wells and Rami Hannoush discussed the company's origin and EpiBiologics' differentiated protein degradation approach. Dr. Mubadala Capital Ventures General Partner Sep 2021. D. PMID: 29632413 DOI: 10. hannoush. Rami Hannoush, Ph. Biomarker interview with Rami Hannoush, Ph. EpiBiologics Executive Team & Key Decision Makers. Rami Hannoush, Ph. D. D. com. Rami Hannoush, Ph. Synthetic protein lipidation. EpiBiologics - a biotechnology company advancing a next-generation antibody-based protein degradation platform and pipeline for membrane and extracellular drug targets - recently announced the company brought the total series A round to $73 million with the addition of $23 million from new investors Digitalis Ventures, Taiho Ventures, and existing investor Codon Capital. Back. Question: Add details. H. com. D. Genentech, McGill, Harvard, Versant Ventures. EpiBiologics, Inc. ’s Post Rami Hannoush, Ph. Citizen and Immigration Services (USCIS) 2019 Outstanding. 4 the Department of Early Discovery Biochemistry, Genentech, South San Francisco, California 94080, and hannoush. Welcome, Rami Hannoush, Ph. Back [email protected] last, after 43 years since the discovery of the Wnt gene, the structure of the ternary Wnt – Frizzled – LRP6 signaling complex is reported here, and it…Tracking Wnts throughout such processes will present a challenge, but might be facilitated by emerging techniques, such as a method for metabolic labeling of palmitoylated Wnts presented by Rami Hannoush (Genentech, San Francisco, USA) . He brings a unique blend of investment experience and deep drug discovery expertise to our company creation efforts. Search for a company, investor, advisor, limited partner, fund or professional to preview their profile. Rami Hannoush, co-founder and interim CEO of EpiBiologics, discusses the company’s platform technology, how its protein degradation approach expands the potential targets for its therapies; and. When expanded it provides a list of search options that will switch the search inputs to match the. View the profiles of professionals named "Rami D" on LinkedIn. The authors declare no competing financial interests. Rami N Hannoush is part of Stanford Profiles, official site for faculty, postdocs, students and staff information (Expertise, Bio, Research, Publications, and more). … | 79 comments on LinkedInRami Hannoush, Ph. ’s Post Rami Hannoush, Ph. D. Vancouver, BC. Rami N Hannoush, Ph. . Background. Previous affiliations of Rami N. Rami N. Baran . By Ron Leuty – Senior Reporter, San Francisco Business Times. EpiBiologics's CEO is Rami Hannoush What does EpiBiologics do? Founded in 2022, EpiBiologics is a biotechnology company with a focus on antibody-based protein degradation. 1021/ja903745s. THE AURON TEAM A CULTURE OF INNOVATION. D. Based on the protocol by Xinxin Gao and Rami N. We cover Rami's new role at Versant, the founding story of. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 2mo Report this post Report Report. ’s Post Rami Hannoush, Ph. D. Marianne Mertens, [email protected]. Drug Discovery & Development Oncology Wnt and Stem. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 4mo Edited Report this post At last, after 43 years since the discovery of the Wnt gene, the structure of the ternary Wnt – Frizzled – LRP6 signaling complex is reported here, and it provides a blueprint that. D. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 2mo Report this post Report Report. Rami Hannoush, Ph. ’s Post Rami Hannoush, Ph. Here’s everything you need to know about […]Correspondence to Rami N Hannoush. "To our knowledge, no one has identified ligands that bind to the zymogen," said senior author Rami Hannoush, Genentech, South San Francisco, California. Today (2010) M. Wnt ligands are critical for tissue homeostasis and form a complex with LRP6 and frizzled coreceptors to initiate Wnt/β-catenin signaling. Ethics declarations. Xinxin Gao 1and Rami N. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 2mo Report this post Report Report. Human OS cell lines (MNNG/HOS, MG-63, and U2-OS) were treated with increasing concentrations of dynasore or cisplatin, and then the cell. At last, after 43 years since the discovery of the Wnt gene, the structure of the ternary Wnt – Frizzled – LRP6 signaling complex is reported here, and it…At last, after 43 years since the discovery of the Wnt gene, the structure of the ternary Wnt – Frizzled – LRP6 signaling complex is reported here, and it…At last, after 43 years since the discovery of the Wnt gene, the structure of the ternary Wnt – Frizzled – LRP6 signaling complex is reported here, and it…We would like to show you a description here but the site won’t allow us. “We would like to thank Rami Hannoush for his leadership as co-founder and interim CEO and look forward to an exciting next stage of growth for EpiBiologics under Ann’s leadership. Healthcare VC | Life sciences company creation 6dRami Hannoush, Ph. D. ’s Post Rami Hannoush, Ph. interim CEO and co-founder of EpiBiologics and venture partner at Versant Ventures. Auron expands its leadership team with the appointments of David Millan, Ph. Rami Hannoush, Ph. Founders James Wells, Rami Hannoush. See the complete. Rami Hannoush’s Post. Lee-Karlon left another Bay Area biotech company, Altos Labs, in June, according to her LinkedIn. D. D. Jennifer Stockdill, Wayne State University. ACS Chemical Biology editors highlight articles from Volume 4, Issue 7, and speak with authors Rami Hannoush and Domagoj Vucic. D. … | 77 comments on LinkedInRami N. D. rami@gene. D. D. D. Rami N Hannoush is part of Stanford Profiles, official site for faculty, postdocs, students and staff information (Expertise, Bio, Research, Publications, and more). . According to LinkedIn Rami Hannoush started working on 2006, then the employee has changed 9 companies and 12 jobs. Cunningham5,* 1Department of Structural Biology 2Center for Advanced Light Microscopy 3Department of Protein Chemistry 4Department of Discovery Oncology 5Department of Early Discovery Biochemistry Genentech, Inc. The . Back. منشور Rami Hannoush, Ph. Genentech veteran Rami Hannoush, UCSF professor Jim Wells team up to score $50M for protein degradation startup EpiBiologics - San Francisco Business TimesThere are 8 professionals named "Rami D", who use LinkedIn to exchange information, ideas, and opportunities. We cover Rami's new role at Versant, the founding story of. The author has an hindex of 28, co-authored 68 publications receiving 2989 citations. D. Lipid modification of cellular proteins plays diverse roles in the regulation of such proteins' trafficking, signaling and behavior. ’s Post Rami Hannoush, Ph. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 6mo Edited Report this post. That’s what it takes to walk across the stage as a Minds Matter NYC graduate. Rami Hannoush, Ph. D. Hannoush (hannoush. Hannoush joined the Early Discovery Biochemistry department at Genentech in 2006 after completing his postdoctoral fellowship at Harvard and his Ph. 1038/nchembio. D. Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Dr. Rami Hannoush 5d · Edited Report this post Report Report. interim CEO and co-founder of EpiBiologics and venture partner at Versant Ventures. It’s been a terrific two days at #jpm2023, meeting new talent and connecting with friends in pharma and the VC world. D. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 2mo Report this post Report Report. ’s Post Rami Hannoush, Ph. … | 79 comments on LinkedInRami Hannoush, Ph. Lee-Karlon served as. Sponsors and Exhibitors. Prior to his current role, he was a. . EpiBiologics develops antibody-based targeted therapies against. D. Its proprietary EpiTAC platform is a modular antibody-based system that enables the precise degradation of disease-driving membrane and extracellular proteins in a tissue-specific. Recommended articles. EpiBiologics Co-Founder. Scheme 1 S2 . Speakers – APS 2022. D. D. … | 76 comments on LinkedInComing out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. Coming out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. Founded Date 2022. EpiBiologics - a biotechnology company advancing a next-generation antibody-based protein degradation platform and pipeline for membrane and extracellular drug targets - recently announced the company brought the total series A round to $73 million with the addition of $23 million from new investors Digitalis Ventures, Taiho. Hannoush's 87 research works with 3,279 citations and 10,017 reads, including: Synthetic Multivalent Disulfide-Constrained Peptide Agonists Potentiate Wnt1/β-Catenin. 2015. , joined the Early Discovery Biochemistry department at Genentech in 2006 after completing his postdoctoral fellowship at Harvard and his Ph. Background. … | 79 comments on LinkedInCongratulations to our own Rami Hannoush, Principal Scientist, Early Discovery Biochemistry, for being one of ten to receive the U. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 2mo Report this post Report Report. Unparalleled access to new data & case studies from globally recognized speakers across the entire landscape of oligonucleotides, peptides, mRNA, genome. - Most recent fund raising on April 28, 2023 raised $30,030,000 in EquityAt last, after 43 years since the discovery of the Wnt gene, the structure of the ternary Wnt – Frizzled – LRP6 signaling complex is reported here, and it…Rami Hannoush . CSB 243: Biotechnology and Development of Therapeutics (Autumn) Regeneration of the adult intestinal epithelium is mediated by a pool of cycling stem cells, which are located at the base of the crypt, that express leucine-rich-repeat-containing G-protein-coupled receptor 5 (LGR5). D. Rami Hannoush, PhDPrincipal Scientist & Group Leader at Genentech. Read top stories published by MubadalaVentures. hannoush. , Partner at Apollo Health Ventures, will join the Company as Board observers. Back. Here, we determined a crystal structure of human FZD7 CRD unexpectedly bound to a 24-carbon fatty acid. Yen, founder and CEO. 120. PMID: 24292069 DOI: 10. hannoush. Rami Hannoush, Ph. Manage my profile. Our mission is to partner with visionary founders building enduring technology companies, and support them with Mubadala’s global scale, resources. This button displays the currently selected search type. D. 11mo Report this comment Report Report. Biography. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 2mo Report this post Report Report. 1007/978-1-61779-349-3_7 Abstract Methods to detect and characterize cellular protein myristoylation and palmitoylation are invaluable in cell biology, immunology, and virologyXinxin Gao, Natalia Arenas-Ramirez, Suzie Scales and Rami Hannoush performed experiments. Connect Lana Janes, Ph. D. 1073/pnas. … | 80 comments on LinkedInComing out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. Hannoush is a general partner at Mubadala Capital, the financial investment arm of the Sovereign Wealth Fund Mubadala. Supplementary Text and Figures. Mar 22, 2023. , 1 DNA Way, South San Francisco, CA 94080, USA. Ribonucleic acids (RNA) are polymers of ribonucleotides linked together by 3',5. Drug Discov. Manage my profile. Genentech Inc. Patrick Sexton, Monash University. Rami Hannoush, Ph. Published on July 20, 2022. ” Prior to EpiBiologics, Dr. , South San Francisco, California, USA. Biomarker interview with Rami Hannoush, Ph. D. Thrilled to share this work from my former group at Genentech, reporting on a new class of peptide agonists that modulate. ’s Post Rami Hannoush, Ph. D. Rami N Hannoush Adjunct Professor, Chemical and Systems Biology Operations Print Profile Email Profile Bio Bio Professional Contact. Rami Hannoush, Ph. Rami brings over 17 years of R&D experience at both large and small biotechnology companies. 1038/nprot. The author has contributed to research in topics: Wnt signaling pathway & Frizzled. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 3mo. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 4mo Report this post Coming out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. D. D. Related to: Rana Hannoush, 42. Additional Details: 1000 Ask Question Find a Lawyer. Rami Hannoush: Chemical tools to perturb and image Wnt signaling: Danica Galonic Fujimori: 3/15/12: Harmit Malik, Fred Hutchinson Cancer Center: Genetic conflicts: the usual suspects and beyond: John Gross: 4/5/12: Ian Wilson, Scripps: Broad neutralization of HIV and influenza viruses: Bob Stroud:It started with a cup of coffee and a slow burning desire to go early and long in the biotech creation business. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 7 شهر تم التحريرRami Hannoush, Ph. D. Healthcare VC | Life sciences company creation 6dRami Hannoush, Ph. Lee-Karlon served as. Rami Hannoush, co-founder and interim CEO of EpiBiologics, discusses the company’s platform technology, how its protein degradation approach expands the potential targets for its therapies; and. ’s Post Rami Hannoush, Ph. Correspondence to Rami N Hannoush or Sachdev S Sidhu. This past Saturday, the Class of 2023…Biomarker interview with Rami Hannoush, Ph. Profile Previews—Driven by the PitchBook Platform. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 3mo Edited Report this post At last, after 43 years since the discovery of the Wnt gene, the structure of the ternary Wnt – Frizzled – LRP6 signaling complex is reported here, and it provides a blueprint that. degree at McGill University. com. D. phone number. Expand search. Rami Hannoush, Ph. D. Congratulations to our own Rami Hannoush, Principal Scientist, Early Discovery Biochemistry, for being one of ten to receive the U. D. Xinxin Gao, Xinxin Gao. Rami Hannoush is a co-founder, President and interim CEO of EpiBiologics. Inventors: Stefan Dengl, Rami Hannoush, Simon Theodor Hansen, Peter Michael Huelsmann, Robert Franklin Kelley, Hubert Kettenberger, Shrenik Chetan Mehta, Devin Brent Tesar HYALURONIC ACID BINDING DERIVATIVES OF VERSICAN (VG1) FOR LONG ACTING DELIVERY OF THERAPEUTICSRead all stories published by MubadalaVentures in 2022. Rami Hannoush, Ph. Fairbrother, ,* and Christian N. Noah Z. The 2020 program will feature invited talks from academic. Department of Protein Engineering, Genentech, Inc. Rami Hannoush, Ph. Hannoush and Phil S. The authors would like to acknowledge Dr. Rami Hannoush, Ph. Healthcare VC | Life sciences company creation | Former R&D leader, GenentechTimelines in Drug Development are more important than ever before. 2015 Oct:28:39-46. and Jim Wells to the portfolio. When expanded it provides a list of search options that will switch the search inputs to match the. D General Information. Damtra, Masad (Supervisor) Abstract. ’s Post Rami Hannoush, Ph. ’s Post Rami Hannoush, Ph. Name & Title Social Contact Info; Craig Lichtenstein. Back Submit. D.